TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06100289: An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Who Ach

Sponsor: Takeda · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT06100289 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06100289 Rescue Dossier →